Federal policy relating to trade tariffs, strengthening domestic generic production and market access barriers for generic pharmaceuticals.
2025 · 4th Quarter (Oct 1 - Dec 31)
APOTEX CORPORATION
Filed by GOVERNMENT COUNSEL, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 19, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- GOVERNMENT COUNSEL, LLC
- Client
- APOTEX CORPORATION
- Filing UUID
- 0e73929a-efb4-4c5a-a7de-241c1d14f0a0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.